MyD88 is an adaptor protein involved in the innate immune response.1,2 It is composed of an N-terminal death domain, intermediate domain, and C-terminal toll-interleukin-1 receptor (TIR) domain.1 It is expressed in both myeloid and non-myeloid tissues, and its expression can be induced by immune-related factors, such as IL-6, LPS, and IFNs.2 As an adaptor protein, the TIR domain of MyD88 interacts with the TIR domain of toll-like receptor 1 (TLR1), -2, -4, -5, and -6, and IL-1 receptor (IL-1R) at the plasma membrane and TLR7, -8, and -9 at the endosomal membrane, while the MyD88 death domain interacts with IL-1R-associated kinases (IRAKs).1,3 In this way, MyD88 translates signals from TLRs and IL-1Rs to IRAKs, inducing signaling that leads to activation of NF-κB and subsequent cytokine production, as well as MAPK signaling.1,2 MyD88 is associated with inflammatory carcinogenesis but is also associated with protection from oncogenic pathogens.4 Mice deficient for Myd88 are protected from endotoxic shock induced by the TLR4 agonist LPS but have an increased susceptibility to bacterial pathogens and parasites.1 A leucine-to-proline mutation at position 265 of MYD88, within the TIR domain, is associated with certain cancers, including Waldenström’s macroglobulinemia and activated B cell diffuse large B cell lymphomas.5 Cayman’s MyD88 (N-Term) Rabbit Monoclonal Antibody (Clone RM306) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.WARNING This product is not for human or veterinary use.
